Michael Albeck

4.0k total citations
129 papers, 3.1k citations indexed

About

Michael Albeck is a scholar working on Organic Chemistry, Molecular Biology and Toxicology. According to data from OpenAlex, Michael Albeck has authored 129 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Organic Chemistry, 28 papers in Molecular Biology and 23 papers in Toxicology. Recurrent topics in Michael Albeck's work include Organoselenium and organotellurium chemistry (23 papers), Spine and Intervertebral Disc Pathology (10 papers) and Cerebrospinal fluid and hydrocephalus (9 papers). Michael Albeck is often cited by papers focused on Organoselenium and organotellurium chemistry (23 papers), Spine and Intervertebral Disc Pathology (10 papers) and Cerebrospinal fluid and hydrocephalus (9 papers). Michael Albeck collaborates with scholars based in Israel, Denmark and United States. Michael Albeck's co-authors include Benjamin Sredni, Yona Kalechman, F. Gjerris, S. E. B�rgesen, Uzi Gafter, F. Shalit, Amnon Albeck, Adi Shani, John Hauerberg and Dan L. Longo and has published in prestigious journals such as Nature, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Michael Albeck

128 papers receiving 3.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Albeck Israel 32 610 584 553 538 503 129 3.1k
Djordje Miljković Serbia 33 95 0.2× 1.1k 1.9× 270 0.5× 1.3k 2.5× 417 0.8× 159 4.0k
Weixiong Zhong United States 41 199 0.3× 2.3k 4.0× 116 0.2× 548 1.0× 217 0.4× 117 4.7k
Michał Woźniak Poland 30 74 0.1× 1.3k 2.2× 97 0.2× 163 0.3× 462 0.9× 147 3.4k
Sushovan Guha United States 51 195 0.3× 3.3k 5.6× 296 0.5× 844 1.6× 265 0.5× 166 7.7k
E. A. de Bruijn Belgium 32 192 0.3× 2.0k 3.4× 95 0.2× 304 0.6× 134 0.3× 128 4.9k
Patrick J. Creaven United States 35 77 0.1× 1.4k 2.3× 130 0.2× 164 0.3× 226 0.4× 127 3.9k
John J. McGuire United States 36 43 0.1× 1.9k 3.2× 136 0.2× 225 0.4× 1.1k 2.1× 176 4.9k
Julien Verrax Belgium 34 334 0.5× 3.1k 5.3× 50 0.1× 322 0.6× 369 0.7× 53 5.0k
Carole Nicco France 37 135 0.2× 2.2k 3.7× 80 0.1× 1.3k 2.4× 316 0.6× 107 5.2k
Emma D. Deeks New Zealand 41 48 0.1× 1.4k 2.3× 185 0.3× 528 1.0× 500 1.0× 156 5.0k

Countries citing papers authored by Michael Albeck

Since Specialization
Citations

This map shows the geographic impact of Michael Albeck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Albeck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Albeck more than expected).

Fields of papers citing papers by Michael Albeck

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Albeck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Albeck. The network helps show where Michael Albeck may publish in the future.

Co-authorship network of co-authors of Michael Albeck

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Albeck. A scholar is included among the top collaborators of Michael Albeck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Albeck. Michael Albeck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kalechman, Yona, Hagit Hauschner, Tal Cohen, et al.. (2024). Inhibition of α4β1 Integrin Activity by Small Tellurium Compounds Regulates PD-L1 Expression and Enhances Antitumor Effects. International Journal of Biological Sciences. 20(11). 4407–4423. 1 indexed citations
2.
Kalechman, Yona, et al.. (2014). Sensitizing B- and T- cell Lymphoma Cells to Paclitaxel/Abraxane–Induced Death by AS101 via Inhibition of the VLA-4–IL10–Survivin Axis. Molecular Cancer Research. 13(3). 411–422. 16 indexed citations
3.
Berrébi, Alain, Maor H. Pauker, Alon Silberman, et al.. (2014). Redox Modulation of Adjacent Thiols in VLA-4 by AS101 Converts Myeloid Leukemia Cells from a Drug-Resistant to Drug-Sensitive State. Cancer Research. 74(11). 3092–3103. 60 indexed citations
4.
5.
6.
Kremer, Melanie, K.‐M. Hanschmann, Sarah Krause, et al.. (2008). Antitumour effects in mycosis fungoides of the immunomodulatory, tellurium-based compound, AS101. British Journal of Dermatology. 158(3). 578–586. 23 indexed citations
7.
Albeck, Michael, et al.. (2007). The Synthetic Tellurium Compound, AS101, Is a Novel Inhibitor of IL-1 β Converting Enzyme. Journal of Interferon & Cytokine Research. 27(6). 453–462. 29 indexed citations
8.
Weil, Merav, Michael Albeck, Alpha Peled, et al.. (2006). The immunomodulator AS101 induces growth arrest and apoptosis in Multiple Myeloma: Association with the Akt/Survivin pathway. Biochemical Pharmacology. 72(11). 1423–1431. 37 indexed citations
9.
Ahlburg, Peter, et al.. (2005). [Surgery for lumbar disc prolapse on an outpatient basis].. PubMed. 167(17). 1852–5. 3 indexed citations
10.
Okun, Eitan, et al.. (2005). Upregulation of carp GDNF mRNA by the immunomodulator AS101. Developmental & Comparative Immunology. 30(5). 441–446. 9 indexed citations
11.
Kalechman, Yona, Uzi Gafter, Talia Weinstein, et al.. (2004). Inhibition of Interleukin-10 by the Immunomodulator AS101 Reduces Mesangial Cell Proliferation in Experimental Mesangioproliferative Glomerulonephritis. Journal of Biological Chemistry. 279(23). 24724–24732. 39 indexed citations
12.
Kalechman, Yona, Uzi Gafter, Rivka Gal, et al.. (2002). Anti-IL-10 Therapeutic Strategy Using the Immunomodulator AS101 in Protecting Mice from Sepsis-Induced Death: Dependence on Timing of Immunomodulating Intervention. The Journal of Immunology. 169(1). 384–392. 112 indexed citations
13.
Albeck, Amnon, Hana Weitman, Benjamin Sredni, & Michael Albeck. (1998). Tellurium Compounds:  Selective Inhibition of Cysteine Proteases and Model Reaction with Thiols. Inorganic Chemistry. 37(8). 1704–1712. 92 indexed citations
14.
15.
Milman, Nils & Michael Albeck. (1995). Distinction Between Homozygous and Heterozygous Subjects with Hereditary Haemochromatosis Using Iron Status Markers and Receiver Operating Characteristic (ROC) Analysis. Clinical Chemistry and Laboratory Medicine (CCLM). 33(2). 95–98. 5 indexed citations
16.
Vonsover, A, Shoshana Loya, Benjamin Sredni, et al.. (1992). Inhibition of the Reverse Transcriptase Activity and Replication of Human Immunodeficiency Virus Type 1 by AS 101 In Vitro. AIDS Research and Human Retroviruses. 8(5). 613–623. 17 indexed citations
17.
Kalechman, Yona, Michael Albeck, & Benjamin Sredni. (1992). In vivo synergistic effect of the immunomodulator AS101 and the PKC inducer bryostatin. Cellular Immunology. 143(1). 143–153. 15 indexed citations
18.
Albeck, Michael, Flemming Madsen, Aase Wagner, & F. Gjerris. (1991). Fracture of the lumbar vertebral ring apophysis imitating disc herniation. Acta Neurochirurgica. 113(1-2). 52–56. 17 indexed citations
19.
Kalechman, Yona, et al.. (1990). Radioprotective effects of the immunomodulator AS101.. The Journal of Immunology. 145(5). 1512–1517. 30 indexed citations
20.
Albeck, Michael & Sason Shaik. (1975). Identification of tellurium-containing compounds by means of mass spectrometry. Journal of Organometallic Chemistry. 91(3). 307–313. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Djordje Miljković Breakdown of academic impact, for papers by Weixiong Zhong Breakdown of academic impact, for papers by Michał Woźniak Breakdown of academic impact, for papers by Sushovan Guha Breakdown of academic impact, for papers by E. A. de Bruijn Breakdown of academic impact, for papers by Patrick J. Creaven Breakdown of academic impact, for papers by John J. McGuire Breakdown of academic impact, for papers by Julien Verrax Breakdown of academic impact, for papers by Carole Nicco Breakdown of academic impact, for papers by Emma D. Deeks
Rankless by CCL
2026